At a Senate hearing on Wednesday, Robert F. Kennedy, Jr., referred to ibogaine as the most promising treatment for PTSD and depression “that anybody’s ever seen.” Does the science hold that up?

This naturally occurring substance, derived from an African shrub, has been used to treat PTSD, brain trauma, depression, addiction and other disorders.

When Jason Prinzo was diagnosed with depression, he was five years old. His father was an alcoholic and a drug addict who was prone to violence, and therapy became a fixture in his childhood. But in sixth grade,

Trump said on Saturday the directive would “dramatically accelerate” access to research and potential treatments.

The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational psychedelic therapy, COMP360, in treatment-resistant depression (TRD), while also awarding the NDA with a Commissioner’s National Priority Voucher (CNPV).

Emerging evidence suggests nitrous oxide provides rapid relief for treatment-resistant depression. But is the therapy ready for the clinic?